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Ling Yao1†, Kai Li1†, Wenting Peng1, Qiang Lin2, Shan Li1, Xin Hu1†, Xinmin Zheng3 and Zhiming Shao1*Abstract
Purpose: To clarify the roles of a new aberrantly spliced transcript of FAK that lacks exon 26 (denoted −26-exon
FAK) in human breast cancers.
Methods: Transcripts of FAK expressed in 102 human breast tumor tissues and 52 corresponding normal tissues
were analyzed by RT-PCR and DNA sequencing, as well as agarose gel electrophoresis. The cDNA of −26-exon
FAK was cloned and expressed in MCF-10A cells, and then the kinase activity, cellular localization and migration
capability of FAK were examined by western blotting, immunofluorescent staining and migration assays,
respectively. The expression levels of FAK were analyzed by western blotting in MCF-7 cells treated with TNF-α
or in MCF-10A cells upon serum deprivation. The MCF-10A cells transfected with a plasmid expressing −26-exon
FAK were cultured in serum-free medium and cell apoptosis was analyzed by flow cytometry.
Results: The −26-exon FAK transcript was exclusively present in human breast tumor tissues and the encoded
protein possessed the same kinase activity, cellular localization and cell migration-promoting ability as wild-type
FAK. In MCF-7 cells treated with TNF-α, and in MCF-10A cells upon serum deprivation, the −26-exon FAK was
resistant to proteolysis while wild-type FAK was largely cleaved. In addition, the −26-exon FAK, but not wild-type
FAK, inhibited cell apoptosis.
Conclusions: The −26-exon FAK transcript, which is exclusively expressed in human breast tumor tissues, encodes
a protein that possesses the same kinase activity and biological function as the wild-type FAK, but because it is
resistant to the caspase-mediated cleavage that induces the proteolysis of the wild-type form, it ultimately
prevents apoptosis.
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FAK is a non-receptor tyrosine kinase that plays a key
role at focal adhesion sites by promoting cell spreading,
migration, and the transmission of anchorage-dependent
anti-apoptotic signals [1]. FAK is activated via auto-
phosphorylation and phosphorylation by other tyrosine
kinases, including the Src family of kinases [2]. Its auto-
phosphorylation at the Tyr-397 site is an important
event for maintaining the biological function of FAK,* Correspondence: shaozmyl@126.com
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unless otherwise stated.because it creates a high-affinity binding site for proteins
with SH2 domains, including the Src family kinases,
which will further phosphorylate FAK on other tyrosine
residues, such as Tyr-576 and 577, to positively up-
regulate FAK activity. The C-terminal region of FAK
contains two proline-rich sequences [2] and also harbors
a focal adhesion-targeting (FAT) sequence that associ-
ates with other proteins, including paxillin [3]. FAK is an
important mediator of cell proliferation, migration, and
survival, and any perturbation of these processes is often
associated with the development of malignancy. In fact,
increased FAK levels have been reported in many types
of cancers, including prostate, cervix, colon, ovary, and
breast cancer [1]. FAK may promote tumorigenesis by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tosis and promoting the survival of tumor cells [5-7],
and modulating focal adhesion dynamics and the cellular
cytoskeleton to facilitate cancer cell invasion and metas-
tasis [8,9].
Apoptosis plays a key role in regulating tissue develop-
ment and preventing cancer metastasis [10]. During the
progression of apoptosis, the executioner caspases
caspase-3 and caspase-7 are major effector caspases that
can proteolyze a large number of substrates, including
FAK, to accelerate apoptosis [10,11]. Apoptosis can be
initiated when adherent cells detach from the basement
matrix, a process which is generally defined as “anoikis”
[10]. However, the evasion of anoikis is frequently ob-
served in FAK-overexpressing or -mutated tumors
[11,12]. Thus, the expression level and activity of FAK is
closely associated with tumorigenesis, which indicates
that FAK may be an important and useful cancer marker
for future cancer diagnosis and therapy [1,2,8,9]. Previ-
ous studies have revealed that the post-transcriptional
regulation of FAK is conserved in rodents and humans,
and the pathological disturbance of alternatively spliced
FAK may lead to abnormal cellular regulation and even
tumorigenesis [13,14]. Thus, we analyzed the FAK ex-
pression at the RNA level in human breast cancer, aim-
ing to explore whether there are alternatively spliced
transcripts of FAK in tumors and to dissect the roles of
these FAK transcripts in tumorigenesis.
In this study, we found that an aberrantly spliced tran-
script of FAK kinase missing the exon 26 segment is ex-
clusively expressed in human breast cancer and that this
FAK mutant is resistant to caspase-mediated proteolysis,
even though it possesses the same kinase activity as
wild-type FAK. Moreover, this FAK mutant inhibited
apoptosis when cultured in serum-free medium. Thus,
we propose that the exon 26-deletion mutant of FAK
may promote the progression of breast cancer by resist-
ing apoptosis and promoting tumor cell survival.
Materials and methods
RNA extraction and real-time PCR
Both breast tumor and corresponding normal tissues were
acquired from the Mammary Gland Branch of the Shanghai
Cancer Center. Fresh tissue samples weighing ~25 mg
were homogenized twice on ice for 20 s with a PowerGen
Model 125 Homogenizer (Fisher Scientific, MA, USA) in
1.5-ml microcentrifuge tubes containing 0.5 ml of the
TRIzol RNA isolation reagent (Invitrogen, NY, USA) ac-
cording to the manufacturer’s instructions. The cDNAs
were reversely transcribed using Superscript II (Invitrogen,
NY, USA), and PCR was performed using the Platinum®
Taq DNA polymerase (Invitrogen, NY, USA) according to
the manufacturer’s instructions. The PCR primers used
are the following: FAK sense, 5’-gccttaacaatgcgtcagtttgacc;FAK antisense, 3’-tcagtgtggtctcgtctgcccaag. The PCR prod-
ucts were cloned using an Original TA Cloning Kit
(TaKaRa, Japan), according to the manufacturer’s instruc-
tions, and five clones were then randomly selected for se-
quencing. The real-time PCR was performed with SYBR
Premix Ex Taq™ (TaKaRa, Japan) according to the manu-
facturer’s instructions. The primers for segment 1 (1304
to 1416 bp) of FAK: forward, 5’-ccatccctaaccattgcg-3’;
reverse, 5’-gcccgttcaccttctttct-3’. The primers for seg-
ment 2 (2546 to 2646 bp) of FAK: forward, 5’-ggctac
cctggttcacat-3’; reverse, 5’-ctgccacattgctatctcct-3’. The
primers for GAPDH: forward, 5’-tgggctacactgagcaccag-
3’; reverse, 5’-gggtgtcgctgttgaagtca-3’.
Cell culture
Both the MCF-10A and MCF-7 cell lines were purchased
from the American Type Culture Collection (ATCC, VA,
USA). The MCF-7 cells were grown in DMEM (Gibco,
NY, USA) containing 10% (v/v) fetal bovine serum (FBS)
(Hyclone, UT) supplemented with 100 μg/ml sodium
pyruvate, 10 μg/ml insulin (Sigma, MO, USA), 100 units/
ml penicillin, and 100 μg/ml streptomycin. The MCF-10A
cells were cultured in DMEM/F12 (Invitrogen, NY, USA)
containing 10% (v/v) horse serum (Invitrogen, NY, USA)
supplemented with 20 ng/ml EGF (PeproTech), 0.5 mg/
ml hydrocortisone (Sigma, MO, USA), 100 ng/ml cholera
toxin (Sigma, MO, USA), 10 μg/ml insulin, 100 units/ml
penicillin, and 100 μg/ml streptomycin. For TNF-α induc-
tion, TNF-α was used at a concentration of 50 ng/ml. For
serum-free induction, the MCF-10A cells were cultured in
DMEM/F12 medium containing all of the other compo-
nents except serum.
Construction of gateway plasmids and virus infection
All of the following Gateway reagents and vectors were
purchased from Invitrogen, and all of the procedures
were performed according to the manufacturer’s instruc-
tions. Briefly, the full-length cDNA encoding wild-type
or mutated FAK with a 5’ sequence encoding three HA
epitopes (YPYDVPDYA) was generated by PCR and in-
tegrated into the pDONR™201 vector through a BP reac-
tion to form the entry clones. The correct entry clones
were then used for LR recombination with the pLenti6/
V5-DEST lenti-virus-expressing vector. The successfully
cloned pLenti-DEST constructs were transfected into
293 T cells using the ViraPower™ Lenti-viral Packaging
Mix to produce the lenti-virus. FAK expression was de-
tected by Western blot, and the lenti-virus was amplified
and saved for further use.
Immunoprecipitation and Western blot
The cells were lysed in lysis buffer (50 mM Tris-Cl
pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM
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munoprecipitation, 500 μg of the total cell extract from
each sample was used. The extracts were incubated with
10 μl of HA antibody (Sigma, MO, USA) overnight at 4°C.
Then, 30 μl of protein A/G-agarose beads (Santa Cruz,
CA, USA) were added, and the mixture was incubated
with rocking for 2 h at 4°C. The precipitates were washed
three times with lysis buffer, resuspended in 40 μl of 1×
sample buffer, and then boiled at 100°C for 10 min. The
Western blot was performed according to the protocols
supplied with each antibody. The following antibodies
were used in this study: anti-FAK (BD Biosciences,
1:2000 dilution), anti-Tyr-397 (Cell Signaling, 1:1000 di-
lution), anti-Tyr-576/577 (Cell Signaling, 1:1000 dilu-
tion), anti-caspase-3 (Cell Signaling, 1:1000 dilution),
and anti-caspase-7 (Cell Signaling, 1:1000 dilution). The
intensity of the bands was analyzed using the ImageJ
software (NIH Image).
Immunofluorescent staining and confocal microscopy
The cells were plated onto coverslips coated with 50 μg/
ml bovine plasma fibronectin (Sigma, MO, USA) and
cultured at 37°C for 16 h. The cells were then fixed in
3.7% paraformaldehyde in 0.01 M PBS for 10 min and
permeabilized with 0.01% Triton X-100 for 10 min on
ice. After extensive washing with 0.01 M PBS, the cells
were blocked with 5% BSA in 0.01 M PBS for 30 min at
room temperature and then incubated with primary HA
antibody (1:100 dilution) overnight at 4°C. After washing
three times with 0.01 M PBS, the cells were incubated
with the rhodamine-labeled secondary antibody (1:400
dilution) for 1 h and DAPI (Roche, Nutley, NJ, USA) for
1 min at room temperature and then visualized under a
confocal microscope according to the manufacturer’s
instructions.
Migration assay
MCF-10A cells transfected with wild-type or −26-exon
FAK constructs were plated onto the upper membrane of
transwells (8-μm pore size, Millipore, MA) at a density of
4 × 105 cells for per well and cultured for 12 h. Any non-
migrated cells on the upper membrane were removed
with a cotton swab, and the migrated cells (located on the
lower surface of the filters) were fixed for 5 min in metha-
nol, stained with 0.1% crystal violet, eluted with 33% eth-
ylic acid, and measured at 570 nm to obtain their OD
values. The experiment was repeated three times.
Flow cytometry analysis
For the flow cytometry analysis, MCF-10A cells at a
density of 2 × 105/ml were doubly labeled with PI and
Annexin V-FITC in the dark at room temperature ac-
cording to the instructions provided by the Annexin V-FITC/PI kit (Invitrogen, NY, USA). Each analysis was re-
peated three times.
Ethics statement
All of the human tissues were acquired from the Mammary
Gland Branch of the Shanghai Cancer Center, Shanghai
Medical College, Fudan University. Written informed con-
sent was provided by all of the patients, and the protocols
were performed in accordance with approval from the Ethic
Committee of Fudan University Shanghai Cancer Center
(Permit Numbers 050432-4-1008A).
Statistical analysis
All of the data were analyzed using the SPSS 13.0.0 (SPSS
Inc., Chicago, IL, USA) software, and the comparisons be-
tween two groups were performed using Student’s t-test.
Values of P < 0.05 were considered significant and are in-
dicated by asterisks in the figures.
Results
The −26-exon FAK protein is exclusively expressed in
tumor tissues
To analyze the FAK transcripts in human breast cancer,
the total RNA from both human breast cancer tissues
and corresponding normal tissues were isolated for RT-
PCR analysis. The PCR products were cloned and se-
quenced. Compared with the human FAK NCBI reference
sequence (NM_153831.3), exon 26 of the FAK transcript
from tumor tissues was absent. The absence of exon 26 in
an FAK transcript has been reported and described previ-
ously (GenBank: BC035404) [13], but we found that this
FAK transcript is associated with the mutation of thymine
to cytosine in the exon 33 region (corresponding to the
mutation of Leu to Pro at position 961 at the protein
level), as shown in Figure 1A, b. In this study, this FAK
transcript was denoted −26-exon FAK. As observed in the
schematic view of the FAK molecular structure shown in
Figure 1A, a segment (amino acids 744–789) was absent
in −26-exon FAK (Figure 1A, b) compared with the
wild-type FAK (Figure 1A, a). Of the 102 tumor tissue
samples, the −26-exon FAK variant was observed in 6
samples (Figure 1B). Interestingly, a mutation (thymine
to cytosine) at position 3192 was closely associated with
the exon 26 absence of FAK variant, as this point mutation
(Leu to Pro at 961) was observed in all these 6 tumor sam-
ples but not in the other tissue samples (Figure 1B). This
study focused on elucidating the function of −26-exon
FAK due to the absence of a segment (amino acids 744 to
789), and to avoid the effect of the point mutation (Leu to
Pro at 961) on the −26-exon FAK function, we have “cor-
rected” this point mutation into Leu 961 during the plas-
mids construction. Thus, the −26-exon FAK analyzed in
this study is just lack of the segment (amino acids 744 to
789) compared to the wild-type FAK at the level of
Figure 1 Detection of FAK transcripts in human breast tumor tissues. A. Schematic of the human FAK molecular domains. The wild-type
FAK contains a FERM domain (1–415 amino acid), a kinase domain (416–676 amino acid), and a C-terminus segment (677–1052 amino acid) that
includes two proline-rich regions and a FAT domain (a). Three Tyr phosphorylation sites, i.e., Tyr 397, 576, and 577, were found in both wild-type
FAK (a) and the protein encoded by −26-exon FAK (b), but the latter lacks the segment composed of amino acids 744 to 789, which contains the
caspase-3/-7-like cleavage motif (DQTD) and has a mutation (Leucine mutated to Proline) at the C-terminus (b). B. Occurrence frequency
of −26-exon FAK in normal and breast tumor tissues. The −26-exon FAK is exclusively expressed in tumor tissues. C. Agarose gel electrophoresis
was used to analyze the pattern of FAK gene transcripts in normal and breast tumor tissues. The short splicing product of FAK (−26-exon FAK)
was only observed in tumor tissues. M: marker; N: normal tissue; T: tumor tissue. D. Schematic of the strategy to determine the percentages
of −26-exon FAK expression in tumor samples. E. The percentage of −26-exon FAK expression in tumor samples. The tumor sample 7 and sample
8 did not express the −26-exon FAK. The percentage of −26-exon FAK expression in tumor samples 1 ~ 6 was 30% ~ 90%. F. Examination of
the −26-exon FAK expression in tumor samples by western blot. The tumor samples 1 ~ 5 expressing the −26-exon FAK and the corresponding
normal samples were analyzed by western blot using the anti-FAK antibody. N: normal tissue; T: tumor tissue.
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then subjected to agarose gel electrophoresis to analyze
the pattern of FAK gene transcripts. Short fragments
(−26-exon FAK) were frequently observed in the tumor
tissues but not in the normal tissues (Figure 1C). To de-
termine the −26-exon FAK expression in tumor tissues,
the real-time PCR was performed according to the strat-
egy as show in Figure 1D. The percentage of the −26-exon
FAK expression was calculated using the following for-
mula: Percentage (%) = [2-(Ct1-Ct3) - 2-(Ct2-Ct3)]/2-(Ct1-Ct3) ×
100%. Ct1: Primer 1 pair; Ct2: Primer 2 pair; Ct3: GAPDH.
Samples 1 ~ 6 were the tumor samples expressing the −26-exon FAK, and the percentage of the −26-exon FAK
expression in tumor samples 1 ~ 6 was 30% ~ 90%
(Figure 1E). The tumor samples 7 and 8 were set as control
in which the −26-exon FAK expression was not observed
(Figure 1E). Then, the −26-exon FAK expression in tumor
samples 1 ~ 6 were examined by western blot using the
anti-FAK antibody. It was a pity that the quantity of sam-
ple 6 left was very little and not suitable for western blot
examination. Here, the expression of −26-exon FAK in
samples 1 ~ 5 were examined and it is interesting to find
that, two bands in tumor samples were generally observed
while only one band in corresponding normal samples
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the arrow in Figure 1F) in tumor samples may be due to
the smaller molecular weight of the −26-exon FAK
(~120 kD) compared to the wild-type FAK (~125 kD).
However, development of the specific antibody for −26-
exon FAK would be greatly beneficial for analyzing the
expression and roles of −26-exon FAK in tumors, which
is one of the core aims of our future work.Figure 2 Examination of the kinase activity, cellular localization, and
activity of −26-exon FAK. MCF-10A cells transfected with wild-type or −26-
anti-FAK, and anti-GAPDH antibodies. GAPDH was used as the internal con
equal. The FAK protein was immunoprecipitated and analyzed with anti-FA
anti-Akt-pT473 antibodies. The experiments were repeated three times. B. S
Akt in the −26-exon group compared with the wild-type group, as shown
cellular localization of −26-exon FAK. MCF-10A cells transfected with −26-e
immunofluorescent assay using anti-HA and anti-paxillin antibodies. The −2
paxillin is shown in red, and the nucleus is shown in blue. The zone in the
single-channel images on the right side. Bar = 10 μm. D. Examination of th
with −26-exon or wild-type FAK were subjected to a cell migration assay a
repeated at least three times. Bar = 100 μm. E. Statistical analysis of the num
the −26-exon group, as shown in D. No significant difference was observed
wild-type FAK detected with anti-HA antibody. GAPDH was used as the intThe −26-exon FAK protein has the same characteristics as
the wild-type FAK
To explore the kinase activity of −26-exon FAK, the ex-
ogenous expression of wild-type or −26-exon FAK in
MCF-10A cells was immunoprecipitated and analyzed
with FAK, phosphor-FAK-Y397, phosphor-FAK-Y576/577,
Akt, phosphor-Akt-pS308, and phosphor-Akt-pT473 anti-
bodies (Figure 2A). Akt is a downstream signaling kinasebiological function of −26-exon FAK. A. Examination of the kinase
exon FAK were lysed, and the cell lysates were analyzed with anti-HA,
trol, and the expression levels of wild-type or −26-exon FAK were
K, anti-FAK-pY397, anti-FAK-pY576/577, anti-Akt, anti-Akt-pS308, and
tatistical analysis of the relative expression levels of activated FAK and
in A. No significant difference was observed. C. Examination of the
xon (a) or wild-type HA-FAK (b) were fixed and subjected to an
6-exon FAK protein (a) or wild-type HA-FAK (b) is shown in green,
square frame was enlarged and is presented as individual
e biological function of −26-exon FAK. MCF-10A cells transfected
s described in “Material and methods”. The experiments were
ber of migrated cells in the wild-type group compared with
. F. Examination of the expression levels of −26-exon FAK and
ernal control.
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cell survival through the PI3K/Akt pathway [15]. The −26-
exon FAK possessed the same phosphorylation status as the
wild-type FAK, as shown by the levels of FAK-pY397 and
pFAK-Y576/577, and the phosphorylation statuses of Akt in
cells transfected with wild-type and −26-exon-FAK-encod-
ing plasmids were similar, indicating that the deletion
of exon 26 did not affect the kinase activity of −26-exon
FAK (Figure 2A and B). We then examined the cellular
localization of −26-exon FAK by transfecting the plasmids
into MCAF-10A cells and found that this protein co-
localizes with paxillin at focal adhesions, similarly to wild-
type FAK (Figure 2C, a and b; Additional file 1: Figure S1).
In addition, the cell mobility of MCAF-10A cells transfected
with wild-type and −26-exon FAK-encoding plasmids was
also analyzed, and the results showed that-26-exon FAK
efficiently promotes the migration of MCAF-10A cells,
similarly to the wild-type FAK (Figure 2D, E, and F).
The −26-exon FAK protein is resistant to
caspase-mediated proteolysis
As described in a previous study, a potential caspase-3/
caspase-7-like cleavage site is possibly encoded by exon
26 of FAK [11,12], which indicates that −26-exon FAK
may lose this caspase-like cleavage site. This hypothesis
prompted us to detect the proteolytic status of FAK in
cells during apoptosis. In this study, we used TNF-α to
induce apoptosis as described previously [10], and we
chose the cancer cell line MCF-7 because, unlike normal
cells, tumor cells are sensitive to TNF-α. The HA-tagged
wild-type and −26-exon FAK were expressed in MCF-7
cells for 6, 8, 12, or 18 h and then treated with 50 ng/ml
TNF-α for 2, 6, or 12 h to induce apoptosis. The trans-
fection efficiency of wild-type and −26-exon FAK was
examined (Additional file 1: Figure S2). The proteolytic
fragments of FAK were readily observed in the wild-type
samples but not in the −26-exon samples, and the
degree of proteolysis became more pronounced with an
increase in the period of TNF-α-induction, indicating
that −26-exon FAK is resistant to caspase-mediated pro-
teolysis (Figure 3A and B). To determine whether this
caspase-resistant effect also exists during apoptosis, the
cells were deprived of serum during cell culture. Cells
transfected with the wild-type or −26-exon FAK con-
structs were cultured in medium without serum for
12 h, and then harvested and analyzed using anti-HA,
anti-Akt, anti-Akt-pS308, and anti-Akt-pT473 antibodies
to examine the relative protein expression. GAPDH was
used as the internal control. The FAK proteins were
immunoprecipitated and analyzed with anti-FAK, anti-
FAK-pY397. The cells that were initially deprived of
serum exhibited no significant changes in the phosphor-
ylation levels of FAK and Akt (Figure 3C); however,
the phosphorylation levels of FAK and Akt decreasednotably in the control and wild-type samples cultured in
serum-free medium for 12 h compared with the −26-exon
FAK samples (Figure 3C and D). The expression levels of
caspase-3 and −7 were significantly elevated in the control
group and the wild-type group, which indicates that the
apoptotic pathway was activated and that these caspases
were also activated in the cells cultured in serum-free
medium for 12 h (Figure 3E and F; Additional file 1:
Figure S3). However, the expression levels of caspase-3
and −7 were relatively lower in the −26-exon samples
compared with the wild-type samples, suggesting that-26-
exon FAK is not only resistant to caspase but also capable
of inhibiting apoptosis to some extent (Figure 3E and F;
Additional file 1: Figure S3).
The −26-exon FAK protein promotes cell survival
It has been reported that FAK can promote cell survival
[5-7]. To determine whether the −26-exon FAK inhibits
apoptosis and promotes cell survival, cells transfected
with wild-type or −26-exon FAK constructs were cul-
tured in medium without serum for 12 or 24 h and then
analyzed by flow cytometry using the PI and Annexin V-
FITC double labeling method. The results show that ap-
proximately 3.8%, 12.5%, and 22.1% of the cells in the
wild-type samples are apoptotic with prolonged induc-
tion periods, whereas 4.9%, 5.8%, and 8.2% of the cells in
the −26-exon samples are apoptotic at the same time
points (Figure 4A). Compared with the wild-type group,
the apoptotic ratio in the −26-exon group was notably
decreased (P < 0.05; Figure 4B). These results suggest
that −26-exon FAK inhibits apoptosis and promotes cell
survival.
Discussion
The region composed of amino acids 744 to 789 is ab-
sent in the −26-exon-deletion FAK and has not been re-
ported to interact with other proteins. Thus, we first
attempted to explore the kinase activity and other pro-
files of −26-exon FAK, and the results showed that this
protein acts similarly to wild-type FAK. Previous studies
showed that FAK is a substrate of caspases [11,12], and
we excitingly found that a caspase-sensitive cleavage site
is located in this absent fragment, which prompted us to
examine the degradation status of −26-exon FAK during
apoptosis. This study revealed that −26-exon FAK is in-
deed resistant to proteolysis by caspase. Although sev-
eral other caspase-mediated cleavage sites were also
found in FAK [11,12], in our study the wild-type FAK
was largely proteolyzed, whereas the −26-exon FAK pro-
tein resisted proteolytic degradation, indicating that the
absent region may be the main, or the most sensitive, re-
gion of FAK that can be cleaved by caspases during
apoptosis. It is worth noting that the exon 26 deletion is
often associated with the mutation of Leu to Pro at
Figure 3 Figure 3 The −26-exon FAK protein is resistant to cleavage by caspase-3/-7. A. The −26-exon FAK was found to be resistant to
proteolysis in MCF-7 cells induced with TNF-α. MCF-7 cells transfected with wild-type or −26-exon HA-FAK were treated with TNF-α for different
periods, and then the FAK protein was immunoprecipitated and analyzed. B. Statistical analysis of the relative normalized expression levels of FAK
in the wild-type group compared with the −26-exon group, as shown in A. Compared with the normalized −26-exon group, the expression levels
of FAK in the wild-type group were notably decreased (*P < 0.05). C. The −26-exon FAK was found to be resistant to proteolysis in MCF-10A cells
cultured in serum-free medium. MCF-10A cells transfected with wild-type or −26-exon FAK were cultured in serum-free medium for 12 h,
and then the expression levels of relative protein were examined. D. Statistical analysis of the relative expression levels of activated FAK and
Akt in the wild-type group cultured in serum-free medium for 12 h compared with −26-exon group, as shown in C. Compared with the
normalized −26-exon group, the expression levels of activated FAK and Akt in the wild-type group were notably decreased (*P < 0.05). E.
The −26-exon FAK protein inhibits the activation of caspase-3/-7. MCF-10A cells transfected with wild-type or −26-exon FAK were cultured in
serum-free medium for 12 h and then harvested and analyzed using anti-caspase-3 or anti-caspase-7 antibody. F. Statistical analysis of the relative
expression levels of cleaved caspase-3 and caspase-7 in the −26-exon group cultured in serum-free medium for 0 h or 12 h compared with the
wild-type group, as shown in E. Compared with the wild-type group, the levels of cleaved caspase-3 and −7 in the −26-exon group were
significantly decreased (*P < 0.05).
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FAK. However, the actual function of this mutation re-
mains to be elucidated.
FAK is essential for focal adhesion and cell migration
and harbors anti-apoptosis capability. Adherent cells that
are deprived of the extracellular matrix initiate the apop-
totic process, during which FAK is cleaved and degraded
by activated caspases. However, the −26-exon FAK mu-
tant is resistant to cleavage and exerts its anti-apoptosis
effect to promote tumor cell survival (Figure 4C). Thus,
we hypothesize that −26-exon FAK may help tumor cellsevade apoptosis and promote tumor cell survival during
the process of cancer metastasis when the outer plate of
tumor cells is deprived of cancer-foci and ready for
metastasis. In addition, the notably down-regulated Akt
activation in the wild-type group compared with the −26-
exon FAK group after treatment with serum-free medium
for 12 h (Figure 3C and D) at least partially explains the
phenomenon that −26-exon FAK and not wild-type FAK
can promote cell survival in serum-free medium, which is
in agreement with the previous finding that FAK may pro-
mote cell survival via the PI3K/Akt pathway [15]. In
Figure 4 The −26-exon FAK protein prevents apoptosis in tumor cells. A. Examination of the apoptosis of MCF-10A cells by flow cytometry.
MCF-10A cells transfected with wild-type (a, c, and e) or −26-exon FAK (b, d, and f) were cultured in serum-free medium for 12 or 24 h and then
harvested and analyzed by flow cytometry. The experiments were repeated three times. B. Statistical analysis of the apoptotic ratio of MCF-10A
cells cultured in serum-free medium for 0 h, 12 h, or 24 h, as shown in A. Compared with the wild-type group, the apoptotic ratio in
the −26-exon group was significantly decreased (*P < 0.05). C. A model demonstrating the roles of −26-exon FAK in the promotion of tumorigenesis.
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the caspase-resistant −26-exon FAK may efficiently pro-
mote the invasion of cancer cells, thereby accelerating the
process of tumor metastasis.
To explore whether −26-exon FAK expresses in avail-
able breast tumor cell lines such as BT-474, MCF-7, the
percentage of −26-exon FAK expression was determined
using the strategy as described in Figure 1D and E. It is
interesting to find that the signals of −26-exon FAK ex-
pression were observed in breast tumor cell line BT-549
and HCC1937 (Additional file 1: Figure S4). The results
indicate that −26-exon FAK, the aberrant transcript of
FAK may be widely expressed in a variety of breast tu-
mors, and may become a new marker of breast cancer.
In addition, the breast tumor cell line BT-549 and
HCC1937 may be the useful cell lines for future studies
in clarifying the roles of −26-exon FAK in tumorigenesis.The histological grading of 6 samples expressing the −26-
exon FAK was II ~ III, and the TNM staging was II ~ III
(Additional file 2: Table S1). And 5 out of 6 samples had
lymph node metastasis. Recurrence of the breast tumor
was observed in the Sample-1 patient 2 years after the sur-
gery; pulmonary metastasis was observed in the Sample-5
patient 2 years after the surgery; the Sample-6 patient died
from brain metastasis 1 year after the surgery. From these
results, we speculated that the expression of −26-exon
FAK may correlate with the tumor degree or metastasis to
some extent.
Taken together, the above results indicate that the alter-
natively spliced transcript −26-exon FAK is exclusively
expressed in tumor tissues, efficiently promotes tumor
cell survival by preventing apoptosis, and may be
extremely useful as a new marker for future cancer
diagnosis.
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Additional file 1: Figure S1. MCF-10A cells transfected with −26-exon
or wild-type HA-FAK were fixed and subjected to an immunofluorescent
assay using anti-HA and anti-paxillin antibodies. The −26-exon FAK
protein or wild-type HA-FAK is shown in green, paxillin is shown in red,
and the nucleus is shown in blue. Bar = 50 μm. Figure S2. Examination
of the expression levels of −26-exon FAK and wild-type FAK detected
with anti-HA antibody. GAPDH was used as the internal control.
Figure S3. MCF-10A cells transfected with wild-type or −26-exon FAK
were cultured in serum-free medium for 0, 6 or 12 h and then harvested
and analyzed using anti-caspase-3 or anti-caspase-7 antibody. GAPDH
was used as the internal control. Figure S4. Examination of the −26-exon
FAK expression in breast tumor cell lines. The percentage of −26-exon
FAK expression in MCF10A and breast tumor cell lines was determined
using the strategy as described in Figure 1D and E.
Additional file 2: Table S1. The clinical information of 6 samples
expressing −26-exon FAK.
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